
## Takeshi Hatanaka

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8931520/publications.pdf Version: 2024-02-01



ΤΛΧΕΣΗΙ ΗΛΤΛΝΑΚΑ

#	Article	IF	CITATIONS
1	Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma: Early clinical experience. Cancer Reports, 2022, 5, e1464.	0.6	43
2	Prognostic impact of C-reactive protein and alpha-fetoprotein in immunotherapy score in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: a multicenter retrospective study. Hepatology International, 2022, 16, 1150-1160.	1.9	35
3	Balloon-occluded transcatheter arterial chemoembolization for hepatocellular carcinoma. World Journal of Hepatology, 2018, 10, 485-495.	0.8	31
4	Lenvatinib for Hepatocellular Carcinoma: A Literature Review. Pharmaceuticals, 2021, 14, 36.	1.7	30
5	Analyses of objective response rate, progressionâ€free survival, and adverse events in hepatocellular carcinoma patients treated with lenvatinib: A multicenter retrospective study. Hepatology Research, 2020, 50, 382-395.	1.8	28
6	Early experience of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma BCLCâ€B stage patients classified as beyond up to seven criteria – Multicenter analysis. Hepatology Research, 2022, 52, 308-316.	1.8	25
7	Does firstâ€line treatment have prognostic impact for unresectable <scp>HCC</scp> ?—Atezolizumab plus bevacizumab versus lenvatinib. Cancer Medicine, 2023, 12, 325-334.	1.3	25
8	Effect of 48â€week pemafibrate on nonâ€alcoholic fatty liver disease with hypertriglyceridemia, as evaluated by the <scp>FibroScanâ€</scp> aspartate aminotransferase score. JGH Open, 2021, 5, 1183-1189.	0.7	21
9	Safety and efficacy of atezolizumab plus bevacizumab in elderly patients with hepatocellular carcinoma: A multicenter analysis. Cancer Medicine, 2022, 11, 3796-3808.	1.3	21
10	Realâ€world efficacy and safety of 12â€week sofosbuvir/velpatasvir treatment for patients with decompensated liver cirrhosis caused by hepatitis C virus infection. Hepatology Research, 2021, 51, 51-61.	1.8	20
11	The Role of the Albumin-Bilirubin Score for Predicting the Outcomes in Japanese Patients with Advanced Hepatocellular Carcinoma Treated with Ramucirumab: A Real-World Study. Oncology, 2021, 99, 203-214.	0.9	18
12	Association of early bevacizumab interruption with efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma: A landmark analysis. Hepatology Research, 2022, 52, 462-470.	1.8	18
13	Liver Function Changes in Patients with Hepatocellular Carcinoma Treated with Lenvatinib: Predictive Factors of Progression to Child-Pugh Class B, the Formation of Ascites and the Candidates for the Post-Progression Treatment. Cancers, 2020, 12, 2906.	1.7	17
14	Therapeutic efficacy of lenvatinib as thirdâ€line treatment after regorafenib for unresectable hepatocellular carcinoma progression. Hepatology Research, 2021, 51, 880-889.	1.8	15
15	Impact of Pemafibrate in Patients with Hypertriglyceridemia and Metabolic Dysfunction-associated Fatty Liver Disease Pathologically Diagnosed with Non-alcoholic Steatohepatitis: A Retrospective, Single-arm Study. Internal Medicine, 2021, 60, 2167-2174.	0.3	15
16	Factors predicting overall response and overall survival in hepatocellular carcinoma patients undergoing balloonâ€occluded transcatheter arterial chemoembolization: A retrospective cohort study. Hepatology Research, 2018, 48, 165-175.	1.8	13
17	Impact of the Prognostic Nutritional Index on the Survival of Japanese Patients with Hepatocellular Carcinoma Treated with Sorafenib: A Multicenter Retrospective Study. Internal Medicine, 2019, 58, 1835-1844.	0.3	12
18	A case of conversion hepatectomy for huge hepatocellular carcinoma with adrenal metastasis and vascular invasion after atezolizumab–bevacizumab treatment. Clinical Journal of Gastroenterology, 2022, 15, 776-783.	0.4	10

Τακές Η Ηλτανακά

#	Article	IF	CITATIONS
19	Lenvatinib for Hepatocellular Carcinoma Patients with Nonviral Infection Who Were Unlikely to Respond to Immunotherapy: A Retrospective, Comparative Study. Oncology, 2021, 99, 641-651.	0.9	9
20	Two cases of rapid progression of esophageal varices after atezolizumab–bevacizumab treatment for hepatocellular carcinoma. Clinical Journal of Gastroenterology, 2022, 15, 451-459.	0.4	8
21	A case of conversion hepatectomy for huge ruptured hepatocellular carcinoma after transarterial embolization and lenvatinib therapy. Clinical Journal of Gastroenterology, 2022, 15, 177-184.	0.4	7
22	Efficacy of Zinc Acetate Treatment for Patients with Decompensated Liver Cirrhosis Complicated by Hypozincemia. Biological Trace Element Research, 2022, 200, 497-504.	1.9	6
23	Favorable outcome of retreatment by directâ€acting antivirals for hepatitisÂC patients with daclatasvir plus asunaprevir combination therapy failure. Hepatology Research, 2020, 50, 303-312.	1.8	5
24	The prognosis of elderly patients with hepatocellular carcinoma: A multiâ€center 19â€year experience in Japan. Cancer Medicine, 2023, 12, 345-357.	1.3	5
25	Simple Scoring System for Predicting TACE Unsuitable among Intermediate-Stage Hepatocellular Carcinoma Patients in the Multiple Systemic Treatment Era. Oncology, 2022, 100, 65-73.	0.9	3
26	Efficacy and Safety of the Combination of Nano-Liposomal Irinotecan and 5-Fluorouracil/L-Leucovorin in Unresectable Advanced Pancreatic Cancer: A Real-World Study. Oncology, 2022, 100, 449-459.	0.9	3
27	Efficacy and safety of 12-week sofosbuvir/velpatasvir treatment of patients with decompensated liver cirrhosis caused by hepatitis C virus infection. Acta Hepatologica Japonica, 2020, 61, 276-278.	0.0	2
28	Follow-up after Direct-acting Antiviral Treatment for Chronic Hepatitis C Virus Infection: Most Patients Are Followed Appropriately. Internal Medicine, 2021, 60, 3061-3070.	0.3	1
29	Successful Treatment of Pancreatic Fistula Following Surgery for Congenital Biliary Dilatation with Endoscopic Ultrasound-Guided Transduodenal Drainage. Case Reports in Gastroenterology, 2022, 16, 73-79.	0.3	0